

Case Report

Plexiform fibrohistiocytic tumor in a rare location: zygomatic arch

Yan Tian, Jun Zhou, Jing Zhang, Dongyun Luo, Renyin Chen, Zhihua Zhao

Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Received December 1, 2015; Accepted February 15, 2016; Epub April 1, 2016; Published April 15, 2016

Abstract: A case of plexiform fibrohistiocytic tumor (PFHT) developing in a 3-year-old girl who presented with the right cheek swollen was reported. Histologically, the tumor displayed multiple nodules of plexiform distribution within the deep dermis and subdermal adipose tissue, consists of mononuclear histiocyte-like cells and multinucleated osteoclast-like cells, the nodules is surrounded by spindle fibroblast-like cells. They were positive for vimentin, SMA, MSA, and CD68, but negative for AE1/AE3, desmin, S100, CD34. This case demonstrates that PFHT is a rare soft tissue neoplasm, in head and neck is more rare, various misleading morphological features should be taken into consideration in the diagnosis.

Keywords: Plexiform fibrohistiocytic tumor, zygomatic arch, soft tissue neoplasm

Introduction

Plexiform fibrohistiocytic tumor (PFHT) is an uncommon Mesenchymal neoplasm of low malignant potential, first described by Enzinger and Zhang in 1988 [1]. It usually affects children and young adolescents [2], the median age of the largest series reported was 14.5 years [3], most of them were female. The tumor is usually localized in the upper extremities, head and neck rare, and presents multinodular lesions in deep dermis and subcutaneous tissue. Here, we added a case of PFHT with uncommon location to discuss the clinicopathologic, immunohistochemical, and differential diagnosis.

Clinical history

A 3-year-old girl was admitted for the right cheek bone mass with a month, consciously increased, without pain and heat. A computed tomography scan showed a soft tissue mass of 18.5×16.9 mm on the right side of the front of masseter with low density, compression of adjacent cheekbones (**Figure 1F**). Complete resection of the mass and part of zygomatic, and postoperative patients in stable condition, without recurrence and metastasis.

Materials and methods

The surgical specimen were fixed in 4% buffered formalin, embedded routinely in paraffin and then stained with hematoxylin and eosin. Immunohistochemical use ready-to-use antibodies. The antibodies included CD68, SMA, Vimentin, S-100, CD34, Bcl-2, HMB-45, Desmin, EMA, AE1/AE3, ERG, Caldesmon, β -catenin, Ki-67. Bought used antibody and immunohistochemical staining kits from Roche co., LTD, Set up a control, regular.

Results

Grossly, the tumor measuring $2 \times 2 \times 1$ cm, with zygomatic adhesion, revealed a firm and white-grey cut surface without distinct demarcation. Histologically, the PFHT showed a multiple nodules of plexiform distribution or consist of spindle cell bundle, sometimes small nodules can be fused (**Figure 1A**). The nodules are composed of plexiform proliferation of mononuclear histiocyte-like cells, multinucleated osteoclast-like cells, and spindle fibroblast-like cells components in variable proportions (**Figure 1B**). The mitotic activity was low (<1 /HPF) and no necrosis was seen. Local area can be seen vascular (**Figure 1C**) tumor invasion and bone tissue invasion (**Figure 1D**).




Figure 1. A. Low-power view of plexiform fibrohistiocytic tumor, the tumor displayed multiple nodules of plexiform distribution. B. High-power view of the tumor nodules with mononuclear histiocyte-like cells, multinucleated osteoclast-like cells and spindle fibroblast-like cells. C. The tumor with intravascular tumor thrombus. D. The bone tissue invasion of the tumor. E. Expression of CD68 in histiocyte-like cells and multinucleated osteoclast-like cells. F. The CT revealed on the right side of the front of masseter with low density, compression of adjacent cheekbones.

The tumor cells were positive for CD68 (**Figure 1E**), SMA, and Vimentin, whereas negative for AE1/AE3, S-100, CD34, Bcl-2, HMB-45, Desmin, EMA, ERG, Caldesmon, β -catenin. Proliferative index Ki-67 was approximately 10%.

Discussion

Firstly described by Enzinger and Zhang [1]. PFHT is rare, and has been described in a smaller percentage of cases [4-6]. PFHT have been considered to have a low-grade malignant

risk on account of a high local recurrence rate, it has been reported the recurrence rate up to 40% [10], possible lymph node involvement, and the appearance of distant metastasis [7, 8], 6% cases have metastasized to regional lymph nodes. Local recurrence can be multifocal and will occur 1 to 2 years after initial excision of the lesion [9]. On the whole, PFHT have been found to have a relatively good prognosis after complete excision. It is one month after the complete excision of the lesion, the patients in stable condition, without recurrence and metastasis.

Clinically, the tumor has a slight female predominance, and mainly affects the children and adolescent, the mean age is reported to be roughly 14.5 years [3], it's rare after 30 years. The tumor is known to involve upper extremities especially the fingers and the wrist, followed by lower limb, the trunk can also occur, head and neck rare. Our case is rare cases occurred in head and neck, and reported a rare at home and abroad. PFHT is widely considered a soft tissue tumor, most PFHTs present in the skin. There is only one reported in bone [6]. Characterized by slow growth of solitary painless mass for the skin and subcutaneous, ranging from 0.3-8 cm, most less than 3 cm.

Histologically, the tumor displayed multiple nodules of plexiform distribution, nodules in the deep dermis and subdermal adipose tissue containing plexiform proliferation of mononuclear histiocyte-like cells, multinucleated osteoclast-like cells, and we can see bundles of fibroblast-like spindle cells surrounding these nodules. Based on the main composition is different, the lesions may present one of the three growth patterns. Fibrohistiocytic, fibroblastic, and mixed. In the fibrohistiocytic type, the boundaries clearly nodules are composed of mononuclear histiocyte-like cells, and multinucleated giant cells. The predominant giant cell types often accompanied by the destruction of the bone; In fibroblastic type, mainly by constitute of the long tufted and short beam fibroblast cells; The mixed type with these two kinds of structure. In our case, the lesion was diagnosed as mixed type. Mitotic activity is generally low ($<3/10$ HPF) [11]. It's rarely to see myxoid changes, pleomorphism and cellular atypia. Some cases can be found vascular tumor invasion. Our case have vascular and bone tissue invasion at the same time.

Immunohistochemically, the vast majority of the tumor cells show a consistent immunophenotype, including the histiocytic cells positive for CD68, and the fibroblastic cells stain for SMA, and Vimentin [3]; but absence of AE1/AE3, S-100, CD34, Bcl-2, HMB-45, Desmin, EMA, ERG, Caldesmon, β -catenin. The molecular diagnosis of PFHT was not reliable, because of lack of specific chromosomal hallmarks [12]. Several entities with the plexiform structure, giant cell structure, eosinophilic tissue cell tumor and spindle cells tumor should be taken into consideration in the differential diagnosis. one differential diagnosis of PFHT is cellular neurothekeoma (CNT), both PFT and CNT are likely to occur in young people, and both have similar histological and immunophenotypical, some reports found that PFHT and CNT might have a common histogenesis [13]. But CNT manifest a plexiform pattern consist of nests and fascicles of eosinophilic epithelioid, multinucleated giant cells can occasionally be seen, CNT tend to have more atypical cells and a higher mitotic activity; PFHT displayed multiple nodules consists of mononuclear histiocyte-like cells, multinucleated osteoclast-like cells, and spindle fibroblast-like cells, without epithelioid cells. Other tumors with plexiform structure are easily confused with PFHT such as plexiform schwannoma, plexiform neurofibroma; tumors with giant cell structure should be as a differential diagnosis: giant cell angioblastoma, benign and malignant soft tissue giant cell tumor; some spindle-cell tumors should be identification with PFHT, such as fibromatosis, fibrous hamartoma of infancy, nodular fasciitis, dermatofibroma, deep benign fibrous histiocytoma and so on.

Effective differential diagnosis is required. PFHT is intermediate tumor, and recurrence is high without complete resection, so that some benign tumors were identified with, in this way can as much as possible reduce tumor recurrence.

In conclusion, PFHT is a distinctive rare fibrohistiocytic tumor, occurred in head and neck is rarer. There is no standard systemic treatment, at present extensive surgical resection is the main treatment, long-term follow-up is necessary to perceive any local recurrence, as well as distance metastases. To be familiar with this entity could contribute to avoid misdiagnosis when we face the similar diseases.

Acknowledgements

This work was financially supported by the First Affiliated Hospital of Zhengzhou University.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Zhihua Zhao, Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Tel: 0086-150-366-07301; E-mail: 15036607301@163.com

References

- [1] Enzinger FM, Zhang RY. Plexiform fibrohistiocytic tumor presenting in children and young adults: an analysis of 65 cases. *Am J Surg Pathol* 1988; 12: 818-26.
- [2] Remstein ED, Arndt CA, Nascimento AG. Plexiform fibrohistiocytic tumor: clinicopathologic analysis of 22 cases. *Am J Surg Pathol* 1999; 23: 662-670.
- [3] Taher A, Pushpanathan C. Plexiform Fibrohistiocytic Tumor: A Brief Review. *Arch Pathol Lab Med* 2007; 131: 1135-1138.
- [4] Chou S, Howle J, Chandraratnam E, Achan A. Fine-Needle Aspiration Cytology features of a Recurring Plexiform fibrohistiocytic Tumor in the upper Limb and Review of the literature. *Diagn Cytopathol* 2011; 39: 49-53.
- [5] Jafarian F, McCuaig C, Kokta V, Hatami A, Savard P. Plexiform Fibrohistiocytic Tumor in three Children. *Pediatr Dermatol* 2006; 23: 7-12.
- [6] Yalcinkaya U, Uz Unlu M, Bilgen MS, Yazici Z. Plexiform fibrohistiocytic tumor of bone. *Pathol Int* 2013; 63: 554-558.
- [7] Moosavi C, Fanburg-Smith JC. An update on plexiform fibrohistiocytic tumor and addition of 66 cases from the Armed Forces Institute of Pathology, in honor of Franz M. Enzinger, MD. *Ann Diagn Pathol* 2007; 11: 313-319.
- [8] Chen YC, Hsiao CH, Chen JS, Lio YH. Plexiform fibrohistiocytic tumor: report of one case with regional lymph node metastasis. *Dermatol Sin* 2010; 28: 117-120.
- [9] Harrill JC, Johnston RS. Plexiform Fibrohistiocytic Tumor of the Foot: A Case Report. *J Foot Ankle Surg* 2014; 53: 635-637.
- [10] Lynnhun K, Achan A, Shingde M, Chou S, Howle JR, Sharma R. Plexiform fibrohistiocytic tumour: morphological changes and challenges in assessment of recurrent and metastatic lesions. *Histopathology* 2012; 60: 1156-1167.
- [11] Zemheri E, Özkanlı JF, Fenol S, Ozen F, Durakbağ CU, Zindancı JE, Okur H. Case Report: Mitotically Active Plexiform Fibrohistiocytic Tumor. Hindawi Publishing Corporation; 2013. pp. 3.
- [12] Leclerc-Mercier S, Pedetour F, Fabas T, Glorion C, Brousse N and Fraita S. Plexiform fibrohistiocytic tumor with molecular and Cytogenetic analysis. *Pediatr Dermatol* 2011; 28: 26-29.
- [13] Pasquinelli G. Fibrohistiocytic tumors containing zebra body-like inclusions and fibropositors. *Ultrastruct Pathol* 2010; 34: 366-70.